Drug intelligence / Profile preview

TRP2-P2 agonist dendritic cell vaccine

Development stage: Preclinical
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TRP2-P2 agonist dendritic cell vaccine is a novel C5a agonist-based dendritic cell vaccine developed for the treatment of melanoma. It is constructed by covalently linking a response-selective peptide agonist of C5a (YSFKDMP(MeL)aR) to the known melanoma tumor-related antigen TRP2-P2. This vaccine aims to improve the targeting and presentation of poorly immunogenic tumor-related antigens, thereby enhancing the immune response against melanoma cells. It has been investigated in a murine model, where it showed reduced tumor growth and enhanced survival in mice immunized with the vaccine.

Targets

C5AR1 (Complement C5a receptor 1)

Beyond the preview

Go deeper on TRP2-P2 agonist dendritic cell vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRP2-P2 agonist dendritic cell vaccine.

Explore the full profile